Brief: Portage Biotech Acquires Outstanding Minority Interest Of Invariant Natural Killer T Cell (Inkt) Agonist Platform
20/07/2022 14:33
July 20 (Reuters) - Portage Biotech Inc PRTG.O :
* PORTAGE BIOTECH ACQUIRES OUTSTANDING MINORITY INTEREST OF
INVARIANT NATURAL KILLER T CELL (INKT) AGONIST PLATFORM
Source text for Eikon: ID:nGNXbSrkzn
Further company coverage: PRTG.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Alpha Compute
See all newsBrief: Alpha Compute Corp. Provides Mid-Q2 2026 Update
Brief: Alpha Compute Ai Gpu Launch Update First Large-Scale Nvidia Blackwell Cluster
Brief: Alpha Compute Appoints Tom Richer To Advisory Board To Accelerate Ai Gpu Compute Infrastructure And Confidential Cloud Strategy
Brief: Alphaton Capital Rebrands As Alpha Compute Corp. To Reflect Its Growing Ai Compute Business
Brief: Alphaton Capital Announces $43 Million Ai Infrastructure And Financing Partnership With Vertical Data